Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO)
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO)
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 25, Issue 9, Pages 1709-1718
Publisher
Oxford University Press (OUP)
Online
2014-03-15
DOI
10.1093/annonc/mdu035
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials
- (2013) G. H. Lyman et al. ANNALS OF ONCOLOGY
- Cost Effectiveness of Primary Pegfilgrastim Prophylaxis in Patients With Breast Cancer at Risk of Febrile Neutropenia
- (2013) Maureen J. Aarts et al. JOURNAL OF CLINICAL ONCOLOGY
- Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
- (2012) Florian Weissinger et al. ANNALS OF HEMATOLOGY
- Cost-Utility Analysis of Primary Prophylaxis Versus Secondary Prophylaxis With Granulocyte Colony-Stimulating Factor in Elderly Patients With Diffuse Aggressive Lymphoma Receiving Curative-Intent Chemotherapy
- (2012) Kelvin K.W. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia
- (2011) C. Zwick et al. ANNALS OF ONCOLOGY
- A systematic review of available clinical evidence – filgrastim compared with lenograstim
- (2011) H. Sourgens et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy
- (2010) Gary H. Lyman et al. CANCER
- A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy
- (2010) J. Randolph Hecht et al. Clinical Colorectal Cancer
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
- (2010) M.S. Aapro et al. EUROPEAN JOURNAL OF CANCER
- Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization
- (2010) Enrico Orciuolo et al. LEUKEMIA RESEARCH
- Glycosylation interference on RhoA activation: Focus on G-CSF
- (2010) Letizia Mattii et al. LEUKEMIA RESEARCH
- Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)
- (2010) Sibylle Loibl et al. SUPPORTIVE CARE IN CANCER
- Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party
- (2009) Keith Wheatley et al. BRITISH JOURNAL OF HAEMATOLOGY
- XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy
- (2009) Ulrich Gatzemeier et al. Journal of Thoracic Oncology
- XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
- (2009) A. Engert et al. LEUKEMIA & LYMPHOMA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now